The Relative Strength (RS) Rating for Castle Biosciences climbed into a higher percentile Wednesday, as it got a lift from 65 to 72.
How To Invest In Stocks In Both Bull And Bear Markets
IBD's unique RS Rating identifies technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the trailing 52 weeks compares to other publicly traded companies.
History reveals that the top-performing stocks tend to have an RS Rating of at least 80 in the early stages of their moves. See if Castle Biosciences can continue to rebound and hit that benchmark.
While the stock is not near a proper entry right now, see if it is able to form and break out from a proper chart pattern.
The company posted negative growth for both sales and earnings last quarter.
Castle Biosciences holds the No. 22 rank among its peers in the Medical-Services industry group. GeneDx Holdings, Hims & Hers Health and InfuSystem Holdings are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Improved Price Performance?
